Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Heart failure].

Masayori Yonezawa1, Issei Komuro

  • 1Department of Cardiovascular Science and Medicine, Chiba University, Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 26, 2002
PubMed
Summary

Sudden cardiac death remains a major concern in heart failure patients. Beta-blockers, ACE inhibitors, and ARBs reduce sudden death risk, while amiodarone or ICDs are options for high-risk individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tolvaptan can improve clinical course in responders.

International heart journal·2013
Same author

Insufficient self-care is an independent risk factor for adverse clinical outcomes in Japanese patients with heart failure.

International heart journal·2013
Same author

Endovascular aortic repair increases vascular stiffness and alters cardiac structure and function.

Circulation journal : official journal of the Japanese Circulation Society·2013
Same author

A novel channelopathy in pulmonary arterial hypertension.

The New England journal of medicine·2013
Same author

High incidence of Aggregatibacter actinomycetemcomitans infection in patients with cerebral infarction and diabetic renal failure: a cross-sectional study.

BMC infectious diseases·2013
Same author

Clinical correlation of brachial artery flow-mediated dilation in patients with systemic sclerosis.

Modern rheumatology·2013

Area of Science:

  • Cardiology
  • Pharmacology
  • Sudden Cardiac Death Research

Background:

  • Heart failure survival has improved with medical advances.
  • Sudden cardiac death (SCD) accounts for a significant portion of mortality in heart failure patients (35-65%).
  • Ventricular arrhythmias are a primary cause of SCD in heart failure.

Purpose of the Study:

  • To review the current understanding of sudden cardiac death in heart failure.
  • To evaluate the risks and benefits of antiarrhythmic therapies.
  • To highlight evidence-based strategies for reducing SCD risk.

Main Methods:

  • Review of recent randomized clinical trials.
  • Analysis of data on beta-adrenergic blockers, ACE inhibitors, and ARBs.
  • Evaluation of amiodarone and implantable cardioverter-defibrillator (ICD) therapy.

Main Results:

  • Beta-adrenergic blockers, ACE inhibitors, and ARBs significantly reduce SCD risk in chronic congestive heart failure.
  • Antiarrhythmic drugs carry increased risks in heart failure patients and should generally be avoided.
  • Amiodarone or ICDs are recommended for patients with a history of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF).

Conclusions:

  • Pharmacological therapies like beta-blockers, ACE inhibitors, and ARBs are crucial for preventing SCD in heart failure.
  • Caution is advised with traditional antiarrhythmic drugs due to heightened risks in this population.
  • Implantable cardioverter-defibrillators and amiodarone offer important therapeutic options for high-risk heart failure patients with ventricular arrhythmias.

Related Experiment Videos